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Summary
The use of low-dose aspirin and heparinoids has improved the preg-
nancy outcome in obstetric antiphospholipid syndrome (APS). How-
ever, current treatment fails in 20–30 % of APS pregnancies, raising 
the need to explore other treatments to improve obstetrical outcome. 
Hydroxychloroquine (HCQ) is widely used in patients with autoim-
mune diseases, mainly systemic lupus erythematous (SLE), due to its 
anti-inflammatory, anti-aggregant and immune-regulatory properties. 
Evidence from in vitro and animal models suggests a potential protec-
tive effect of HCQ in obstetric APS. Pending the availability of prospec-
tive trials, we aimed to systematically review the available evidence 
and to assess the clinical judgment of a panel of experts regarding the 
use of HCQ in improving pregnancy outcome in women with anti-
phospholipid antibodies (aPL). Clinical data on the ability of HCQ to 
improve pregnancy outcome in women with aPL are very limited in 
the available literature. Only one cohort study evaluating maternal 
and fetal outcome of pregnancy in patients with SLE who were ex-
posed to HCQ was identified. Four of 14 (29 %) treated with HCQ pa-
tients had pregnancy failure, compared with six of 24 (25 %) of pa-
tients not treated with HCQ. However, the effect of HCQ was not ad-
justed for the use of other medications such as aspirin, heparins or 
steroids. Selected experts were contacted by e-mail and asked to re-
view the summary of the evidence provided by the working group and 
to briefly answer each of the proposed questions. Overall, the panel of 
experts agreed that adding HCQ could be considered in selected cases 
or after failure of standard treatment with aspirin and a heparin 
agent. Specifically, the majority of experts considered adding HCQ in 
specific scenarios, such as women with previous thrombosis (either ar-
terial and/or venous), and/or with previous ischaemic placenta-me-
diated complications. Prospective studies are necessary before the use 
of HCQ during pregnancy in women with aPL should be routinely rec-
ommended for clinical practice.
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Introduction
Antiphospholipid syndrome (APS) is defined by the combination 
of thrombotic events and/or obstetrical morbidity in patients who 
have persistently positive antiphospholipid antibodies (aPL). Lab-
oratory tests to identify aPL includes solid-phase immunoassays 
(ELISA) to detect anticardiolipin (aCL) and anti-β2 glycoprotein I 
(aβ2GPI) antibodies and functional coagulation assays for lupus 
anticoagulants (LAC). The presence of aPL has to be confirmed at 
least in two occasions more than 12 weeks apart (1).
The clinical features of obstetric APS include any of the follow-
ing adverse pregnancy outcomes: 1) otherwise unexplained recur-
rent pregnancy loss before the 10th week of gestation, 2) otherwise 
unexplained fetal death ≥ 10 weeks of gestation, or 3) preterm 
birth before 34 weeks of gestation due to preeclampsia or placental 
insufficiency (1).
The prevention of obstetric complications is based on the use of 
low-dose aspirin and/or subcutaneous injections of unfractionated 
heparin (UFH) or low-molecular-weight heparin (LMWH) (2). 
Women with APS who have had a previous thrombotic event are 
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typically treated with low-dose aspirin and intermediate or full 
anticoagulation doses of a heparin agent (2).
With sound medical and obstetric management, around 70 % of 
pregnant women with APS will deliver a viable live infant (3). 
However, in 20–30 % of APS pregnancies current treatment fails.
Anecdotal reports suggest that hydroxychloroquine (HCQ) 
may improve pregnancy outcome in APS (4, 5). HCQ is tradition-
ally an antimalarial drug, which has been widely used in the treat-
ment of patients with autoimmune conditions, mainly SLE where 
it prevents flares and improves survival (6–8). Evidence supporting 
the protective effects of HCQ in APS is sparse and comes mainly 
from animal models and in vitro findings. HCQ may decrease the 
risk of thrombotic events via inhibition of platelet aggregation and 
release of arachidonic acid from stimulated platelets (9, 10). In aPL 
animal models, HCQ decreases thrombus size after experimentally 
induced vascular injury (10). More recently, HCQ has been shown 
to reverse the binding of aPL-β2GP1 complexes to phospholipid 
bilayers and restore the aPL-disrupted annexin V shield on cell 
surfaces, a possible pathogenic mechanism in the development of 
pregnancy loss and thrombosis in APS (11). Taken together, these 
findings support HCQ treatment as a potential candidate to im-
prove pregnancy outcome in women with aPL. However, high 
level evidence supporting the use of HCQ in pregnant women 
with aPL without SLE are sparse and inconclusive.
Pending the availability of prospective trials, we aimed to sys-
tematically review the available evidence and to assess the clinical 
judgment of a panel of experts regarding the use of HCQ in im-
proving pregnancy outcome in women with aPL.
Methods
A working group (SS, MK, and BJH) performed a systematic re-
view of the literature as detailed below in “Literature search”.
Because it was anticipated that only a very low level of evidence 
could be found, unanswered clinical questions were subsequently 
addressed to internationally recognised experts in the field in 
order to obtain an “evidence-based clinical judgment”. This ap-
proach has been previously described (12) to address a specific 
and clinically relevant question in areas where best clinical practice 
is uncertain.
International experts were selected based on their expertise and 
scientific production in the field. We formulated three clinical pre-
structured questions with multiple choice answers on the use of 
HCQ in patients with aPL during pregnancy. The first question de-
tailed eight potential scenarios in which HCQ treatment of aPL 
positive women without an underlying connective tissue disease 
during pregnancy might be considered. The second question was on 
the duration of therapy with HCQ and on the optimal timing for 
stopping after delivery. The third question was concerning potential 
factors to be considered when prescribing HCQ in pregnancy.
Selected experts were contacted by email and asked to review 
the summary of the evidences provided by the working group and 
to briefly answer each of the proposed questions. Experts were 
blinded to the answers provided by their peers. Based on the clini-
cal judgment provided by the experts, we formulated some practi-
cal suggestions aimed to assist practicing clinicians in their daily 
activity. No formal method for the grading of recommendations 
was applied.
Literature search
A detailed literature search strategy was developed a priori. Keywords 
and subject terms used in the search included: „pregnancy“ [MeSH 
Terms] OR pregnancy [Text Word], AND („hydroxychloro-
quine“[MeSH Terms] OR „hydroxychloroquine“[All Fields])”, AND 
“antibodies, anticardiolipin“[MeSH Terms] OR („antibodies“[All 
Fields] AND „anticardiolipin“[All Fields]) OR „anticardiolipin anti-
bodies“[All Fields] OR („anticardiolipin“[All Fields] AND „anti-
bodies“[All Fields]);” and “antibodies, antiphospholipid“[MeSH 
Terms] OR („antibodies“[All Fields] AND „antiphospholipid“[All 
Fields]) OR „antiphospholipid antibodies“[All Fields] OR („anti-
phospholipid“[All Fields] AND „antibodies“[All Fields])”, „lupus co-
agulation inhibitor“[MeSH Terms] OR („lupus“[All Fields] AND 
„coagulation“[All Fields] AND „inhibitor“[All Fields]) OR „lupus 
coagulation inhibitor“[All Fields] OR („lupus“[All Fields] AND 
„anticoagulant“[All Fields]) OR „lupus anticoagulant“[All Fields]”, 
anti-beta[All Fields] AND 2[All Fields] AND („glycopro-
teins“[MeSH Terms] OR „glycoproteins“[All Fields] OR „glycopro-
tein“[All Fields]) AND 1[All Fields]
The search strategy was applied to Ovid MEDLINE (R) In Pro-
cess & other non-indexed citations and Ovid MEDLINE (R) 1970 
to December 2014.
The grey literature was searched by applying a similar strategy 
into Google Scholar, PubMed and the Proquest Dissertation & 
Theses databases.
Additional references were identified from manual review of 
the reference lists of included articles.
Study selection
Potential studies identified with the above search strategy were ex-
ported to an electronic reference management software program 
(RefWorks v.2.0). Duplicate studies were identified and removed 
using the filter functions “exact duplicates” and “close duplicates.”
Two independent reviewers (SS and BJH) reviewed all potential 
studies. Eligibility was first determined by review of the title and 
abstract and then by full article review. Disagreements were re-
solved by consensus; if consensus was not achieved, a third party 
(MK) provided an assessment of eligibility.
As the data on eligibility was dichotomous (eligible: yes / no), 
inter-rater agreement at both the title and abstract review and the 
full article review stages were determined by calculation of Cohen’s 
kappa coefficient (13).
Inclusion and exclusion criteria
A study was included if it 1) reported on the laboratory investi-
gation of any aPL, 2) reported on pregnancy outcomes, 3) reported 
on therapy with HCQ, and 4) included a control group.
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Studies enrolling patients with underlying autoimmune dis-
orders (e. g. Systemic Lupus Erythematosus, SLE) were also in-
cluded when meeting the above criteria.
Review articles, case report, and case series without a control 
group were excluded from the analysis.  
Data extraction
All the papers were scrutinised for the following: 1) study design 
(retrospective cohort, prospective cohort, case–control, cross-sec-
tional, and case series); 2) number of patients; 3) type of outcome; 
4) number and type of aPL tests used; 5) definition of “positive 
criteria aPL” (low, medium or high titer, or other, when available) 
as per the study’s definition ; 6) confirmation of criteria aPL, at 
least six weeks (1) or 12 weeks (14) apart; 7) presence of control 
group; and 8) use of HCQ during pregnancy.
Results of the literature review
▶ Figure 1 summarises results from the literature research. Only 
one study was included (15). Value of kappa coefficient among Au-
thors was 0.76, reflecting excellent agreement.
Buchanan et al. studied maternal and fetal outcome of pregnan-
cy in patients with SLE positive for aPL who were exposed to 
HCQ. In their cohort, four of 14 (29 %) HCQ patients positive for 
aPL had pregnancy failure, compared with six of 24 (25 %) patients 
who were not exposed to HCQ. There was no difference in inci-
dence of maternal thrombosis between the HCQ and control pa-
tients. However, it worth noting that the study was not designed to 
specifically address the question about the use of HCQ in women 
with aPL during pregnancy . Besides, the effect of HCQ was not 
adjusted for the use of other medications such as aspirin, heparins 
or steroids.
Expert questionnaire results
▶ Table 1 summarises the answers for each question. Additional 
comments provided by the experts were also taken into account 
when interpreting the results.
Question 1: Is there a role for HCQ treatment of aPL 
positive women without an underlying connective 
 tissue disease during pregnancy, and if so, when would 
you consider using it?
Most of the experts (5 out of 7) would not consider the use HCQ 
in an aPL positive primigravida without any history of thrombo-
sis/pregnancy morbidity in addition to aspirin. None of them 
would consider using HCQ in aPL positive woman without any 
history of thrombosis/pregnancy morbidity as an alternative to as-
pirin.
The majority of experts (5 out of 7) stated they would consider 
a role for HCQ in addition to aspirin and/or LMWH in women 
with previous aPL related complications, even though this is not 
part of their current practice.
No agreement was achieved in regards to the use of HCQ in pa-
tients with previous late pregnancy complications, such as late fetal 
loss beyond 10 weeks of gestation or placenta-mediated compli-
cations, even though most of them use/would consider HCQ as 
additional option to aspirin and LMWH in these settings (5 out of 
7 and 4 out of 7, respectively).
Similarly, no unanimous consensus was achieved when experts 
were asked whether to consider HCQ in aPL-positive pregnant 
women with a history of previous venous or arterial thrombosis as 
adjuvant treatment to aspirin and LMWH (4 out of 7 use/would 
consider the use of HCQ).
Figure 1: Literature 
search strategy on the 
association between 
 hydroxycloroquine and 
pregnancy morbidity in 
women with anti-
phospholipid anti-
bodies.
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Question 2: What is the optimal duration of HCQ 
 therapy after pregnancy, if it is used in patients without 
an underlying connective tissue disorder?
No expert agreement was achieved in terms of the duration of 
HCQ (4 out of 7 use/would use HCQ in this setting following a 
similar indication as low dose aspirin). Most of the expert panel 
would not consider a treatment length of six weeks postpartum as 
adequate thromboprophylaxis. Likewise, the panel would not con-
sider a three months postpartum prophylactic dose in this setting 
(5 out of 7).
Question 3: Would you take into account any of the 
 following factors when prescribing HCQ for an aPL-
 positive woman without an underlying connective 
 tissue disease during pregnancy?
Most experts would consider HCQ in aPL positive pregnant 
women with additional factors including triple aPL positivity, 
ANA positivity or cardiovascular risk factors (4 out of 7, 5 out of 7 
and 5 out of 7, respectively). Two of the experts made an additional 
comment, stating that they would consider the use of HCQ in ad-
dition to standard treatment in women with few opportunities for 
further pregnancies, e. g. advancing age and/or concomitant re-
duced fertility.
Practical suggestions based on “evidence and clinical 
judgement”
On the basis of the available evidence and of the clinical judgments 
provided by the seven international experts, we tried to address 
questions that are clinically relevant for the practicing clinician 
dealing with pregnancy in aPL positive women without SLE and to 
provide clinicians with some practical recommendations. As it is 
now widely accepted that all patients with SLE should receive 
HCQ to reduce disease activity and damage (16), the question-
naire focused on the management of women with aPL without 
other underlying connective tissue disease during pregnancy.
As only one low-quality study was found, recommendations 
mostly rely on expert opinion.
Table 1: Summary of the questions and expert opinions.
Question 1: Is there a role for hydroxychloroquine treatment of aPL positive women without an underlying connective tissue disease during 
 pregnancy, and if so, when would you consider using it? 
 aPL positive primigravida without any history of thrombosis/pregnancy morbidity in addition to aspirin
 aPL positive woman without any history of thrombosis/pregnancy morbidity as an alternative to aspirin
 aPL positive woman with an history of 3 or more unexplained consecutive spontaneous abortions before the 10th  week of 
 gestation but no history of thrombosis i.e. proved obstetric APS, in addition to aspirin and/or LMWH 
 aPL positive woman with an history of death of a morphologically normal fetus at or beyond the 10th week in 
 addition to Aspirin and LMWH
 aPL positive woman with an history of eclampsia or severe preeclampsia &/or intrauterine growth restriction &/or   placental
  abruption before 34 weeks, in addition to aspirin and LMWH
 aPL positive woman with a history of venous thrombosis in addition to aspirin and LMWH
 aPL positive woman with a history of arterial thrombosis in addition to aspirin and LMWH?
Question 2: What is the optimal duration of HCQ therapy after pregnancy, if it is used in patients without an underlying connective tissue disorder? 
 duration of hydroxychloroquine treatment should follow the same principles of Aspirin prophylactic use
 treat the patient for 6 weeks after delivery initially and then assess
 treat most patients for 3 months after delivery
Question 3: Would you take into account any of the following factors when prescribing hydroxychloroquine for an aPL positive woman without an 
underlying connective tissue disease during pregnancy?*
 triple aPL positivity
 ANA
 CV risk factor
aPL, antiphospholipid antibodies; LMWH, low-molecular-weight heparin; ANA, anti nuclear antibodies; CV, cardio vascular. * Two of the experts made an additional 
comment, stating that they would consider the use of HCQ in addition to standard treatment in women with few opportunities for further pregnancies (e.g. ad-
vancing age and/or concomitant infertility). 
YES
2
0
1
2
3
3
3
3
2
1
4
4
4
NO
5
7
1
2
3
3
3
3
4
5
3
2
2
Potentially 
but not my 
current 
practice
0
0
5
3
1
1
1
1
1
1
0
1
1
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 d
eg
li S
tu
di
 d
i T
or
in
o.
 C
op
yr
ig
ht
ed
 m
at
er
ia
l.
© Schattauer 2016 Thrombosis and Haemostasis 115.2/2016
289
vious thrombosis, and/or with previous placenta mediated compli-
cations) or after failure of standard treatment with aspirin and a 
heparin agent. Prospective studies are necessary before the use of 
HCQ during pregnancy in women with aPL should more com-
monly be brought into clinical practice.
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Overall, experts agreed that adding HCQ could be considered 
in selected cases or after failure of standard treatment with aspirin 
and a heparin agent. Despite no unanimous agreement, the major-
ity of experts would consider adding HCQ in specific scenarios, 
such as women with previous thrombosis (either arterial and/or 
venous), and/or with previous placenta mediated complications. It 
was also additionally mentioned that age and/concomitant re-
duced fertility could be considered as indications.
Only one expert would consider using HCQ in addition to as-
pirin and/or a heparin agent in the future management of aPL 
positive woman with an history of three or more unexplained con-
secutive spontaneous abortions before the 10th week of gestation 
but no history of thrombosis, i. e., proved obstetric APS.
There was full agreement and easy consensus among experts 
not to consider HCQ as an alternative to aspirin. This option was 
considered only in case of allergy/intolerance to aspirin as an alter-
native to clopidogrel and was pointed out by two experts as an ad-
ditional note.
All of the experts, who support the additional use of HCQ, sug-
gested that the duration of HCQ treatment should follow the same 
principles of low dose aspirin. One could speculate that women 
could start taking HCQ when actively trying to conceive. However, 
no further specific suggestion was proposed about the timing of 
starting HCQ.
Triple positivity for aPL, the presence of ANA and/or concomi-
tant cardiovascular risk factors were factors supporting the use in 
addition to the standard therapy for some experts.
The heterogeneity among expert opinions probably reflects the 
lack of solid data from adequately designed trials to address this 
very question. Currently no international standardised protocols 
for the management of aPL pregnant women are available. Fur-
thermore, when considering women with previous poor pregnan-
cy outcomes despite low dose aspirin and a heparin agent, the 
available evidence regarding treatment is scarce, and the manage-
ment is largely dependent on the expertise of the centres and the 
responsible physician. The different attitude towards the use of 
HCQ may also reflect the different clinical experience of the inter-
viewed clinicians and the current standard of care within the dif-
ferent countries.
The approach proposed has been previously described by 
Ageno et al. (12). In their systematic review, three studies were in-
cluded, being two trials enrolled in a meta-analysis. We extended 
our systematic review beyond randomised controlled trials (RTCs) 
by also including observational studies, due to the lack of available 
RTCs, as considered in the Updated Method Guidelines for Sys-
tematic Reviews in the Cochrane Collaboration Back Review 
Group (17).
In conclusion, evidence of protective effects of HCQ in APS 
similar to the situation in SLE arises from in vitro studies or anec-
dotal reports. Clinical data on the ability of HCQ to improve preg-
nancy outcome in women with aPL are virtually absent.
Until prospective studies are available, unmet clinical questions 
were addressed to internationally recognized experts in the field, 
suggesting that HCQ might be considered in addition to conven-
tional APS treatment in selected cases (such as women with pre-
What is known about this topic?
• The use of low-dose aspirin and heparinoids has improved the 
pregnancy outcome in obstetric APS.
• Anecdotal reports suggest that HCQ may improve pregnancy 
 outcome in APS.
What does this paper add?
• Clinical data on the ability of HCQ to improve pregnancy outcome 
in women with aPL are very limited in the available literature.
• A panel of experts agreed that adding HCQ could be considered 
in selected cases or after failure of standard treatment with 
 aspirin and a heparin agent. 
• Adding HCQ may be considered in specific scenarios, such as 
women with previous thrombosis, and/or with previous ischaemic 
placenta-mediated complications. 
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